$-0.22
(Market cap
$323 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.5
-
Debt to Equity
0
-
Book Value
$2.9
-
EPS
$-1
-
Face value
--
-
Shares outstanding
64,697,402
5 Years Aggregate
CFO
$-142.98 Mln
EBITDA
$-167.39 Mln
Net Profit
$-161.39 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Immuneering Corp (IMRX)
| -24.2 | 14.4 | -6.5 | -3.9 | -19.1 | -28.5 | -- |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Immuneering Corp (IMRX)
| 199.1 | -69.8 | 51.5 | -70.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Immuneering Corp (IMRX)
|
5.0 | 322.8 | 0.4 | -57.3 | -17,219.3 | -28 | -- | 1.8 |
| 84.9 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 72.1 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 105.4 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 351.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.8 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 600.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 344.8 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 144.3 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Immuneering Corp (IMRX)
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat... patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. Read more
-
Co-Founder, President, CEO & Director
Dr. Benjamin J. Zeskind M.B.A., Ph.D.
-
Co-Founder, President, CEO & Director
Dr. Benjamin J. Zeskind M.B.A., Ph.D.
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Immuneering Corp (IMRX)
What is the current share price of Immuneering Corp (IMRX) Today?
The share price of Immuneering Corp (IMRX) is $4.99 (NASDAQ) as of 28-Aug-2026 16:18 EDT. Immuneering Corp (IMRX) has given a return of -19.14% in the last 3 years.
What is the current PB & PE ratio of Immuneering Corp (IMRX)?
Since, TTM earnings of Immuneering Corp (IMRX) is negative, P/E ratio is not available.
The P/B ratio of Immuneering Corp (IMRX) is 1.77 times as on 28-Aug-2026, a 67 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-7.59 |
1.95 |
2024 |
-1.12 |
1.65 |
2023 |
-4.02 |
2.38 |
2022 |
-2.54 |
1.17 |
2021 |
-12.53 |
2.69 |
What is the 52 Week High and Low of Immuneering Corp (IMRX)?
The 52-week high and low of Immuneering Corp (IMRX) are Rs 10.08 and Rs 3.86 as of 30-Aug-2026.
What is the market cap of Immuneering Corp (IMRX)?
Immuneering Corp (IMRX) has a market capitalisation of $ 323 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Immuneering Corp (IMRX)?
Before investing in Immuneering Corp (IMRX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.